{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-006451","form_type":"8-K","ticker":null,"cik":"0001597264","company_name":"Blueprint Medicines Corp","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.150116+00:00","generated_at":"2026-06-03T00:31:18.347071+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Blueprint Medicines Q1 AYVAKIT revenue $92.5M, raises full-year guidance to $390-410M","bullets":["AYVAKIT net product revenue $92.5M in Q1 2024, up >135% YoY from $39.1M.","Full-year AYVAKIT revenue guidance raised to $390-410M from prior $360-390M.","Net income of $89.1M includes a $173.7M non-cash debt extinguishment gain; prior year net loss $129.6M.","Cash, cash equivalents and investments $735.6M as of March 31, 2024, down from $767.2M at year-end 2023.","BLU-808 IND on track for Q2 2024; BLU-222 combination data to be presented at ASCO 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-006451","json":"https://secwatch.observer/filing/0001558370-24-006451.json","markdown":"https://secwatch.observer/filing/0001558370-24-006451.md","text":"https://secwatch.observer/filing/0001558370-24-006451.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1597264/000155837024006451/0001558370-24-006451-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1597264/000155837024006451/bpmc-20240502x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:31:18.347071+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a474a0fddd31d9106df4d9e5eb1ebf23aa886818","claim":"Blueprint Medicines Corp reported the first quarter ended March 31, 2024 results: revenue $92.5 million. Guidance raised.","evidence_excerpt":"-- Achieved $92.5 million in AYVAKIT net product revenues in the first quarter 2024 -- -- Raising guidance to $390 million to $410 million in full year AYVAKIT net product revenues --","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1597264/000155837024006451/0001558370-24-006451-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$92.5 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}